Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer [SUBSTUDY OF 700216591]

Next Previous
X
Search
Trial Profile

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer [SUBSTUDY OF 700216591]

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
  • Indications Carcinoma; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ADAPT; ADAPT HR+/HER2-

    • Most Recent Events

    • 24 Oct 2023 Results (n=4491) assessing the impact of recurrence score, clinical-pathological factors, gene mutations and histology in early HR+/HER2- breast cancer, presented at the 48th European Society for Medical Oncology Congress.
    • 01 Apr 2023 Results published in the Modern Pathology
    • 23 Mar 2023 Planned End Date changed from 1 Sep 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top